Alan W. Partin

58.6k total citations · 20 hit papers
657 papers, 40.3k citations indexed

About

Alan W. Partin is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Surgery. According to data from OpenAlex, Alan W. Partin has authored 657 papers receiving a total of 40.3k indexed citations (citations by other indexed papers that have themselves been cited), including 537 papers in Pulmonary and Respiratory Medicine, 150 papers in Rheumatology and 95 papers in Surgery. Recurrent topics in Alan W. Partin's work include Prostate Cancer Diagnosis and Treatment (460 papers), Prostate Cancer Treatment and Research (450 papers) and Urologic and reproductive health conditions (140 papers). Alan W. Partin is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (460 papers), Prostate Cancer Treatment and Research (450 papers) and Urologic and reproductive health conditions (140 papers). Alan W. Partin collaborates with scholars based in United States, Germany and Austria. Alan W. Partin's co-authors include Jonathan I. Epstein, Patrick C. Walsh, Misop Han, Leslie A. Mangold, Elizabeth B. Humphreys, Charles R. Pound, Bruce J. Trock, Robert W. Veltri, Stephen J. Freedland and Steven Piantadosi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Alan W. Partin

646 papers receiving 38.8k citations

Hit Papers

Combination of prostate-specific antigen, clinical stage,... 1990 2026 2002 2014 1997 2005 1997 1998 2008 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
    1997 1.3k citations Alan W. Partin profile →
  2. Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
    2005 1.0k citations Stephen J. Freedland, Elizabeth B. Humphreys et al. profile →
  3. Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer
    1997 929 citations Alan W. Partin profile →
  4. Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease
    1998 860 citations Alan W. Partin, Michael K. Brawer et al. profile →
  5. Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
    2008 830 citations Rong Hu, Thomas A. Dunn et al. Cancer Research profile →
  6. LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY
    2001 821 citations Misop Han, Alan W. Partin et al. profile →
  7. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
    2001 755 citations Alan W. Partin, Leslie A. Mangold et al. Urology profile →
  8. Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer
    2003 559 citations Misop Han, Alan W. Partin et al. The Journal of Urology profile →
  9. Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years
    1994 555 citations Patrick C. Walsh, Alan W. Partin et al. The Journal of Urology profile →
  10. Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer
    2003 554 citations Misop Han, Alan W. Partin et al. The Journal of Urology profile →
  11. Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia
    1990 506 citations Alan W. Partin, Jonathan I. Epstein et al. The Journal of Urology profile →
  12. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
    2016 489 citations Alan W. Partin et al. profile →
  13. Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience
    2011 485 citations Bruce J. Trock, Patricia Landis et al. Journal of Clinical Oncology profile →
  14. PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY
    1997 484 citations Alan W. Partin, Jonathan I. Epstein et al. profile →
  15. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
    1993 474 citations Alan W. Partin, Jonathan I. Epstein et al. profile →
  16. PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING
    1999 471 citations Alan W. Partin et al. The Journal of Urology profile →
  17. Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy
    2011 468 citations Patrick C. Walsh, Misop Han et al. The Journal of Urology profile →
  18. Prediction of Progression Following Radical Prostatectomy
    1996 457 citations Jonathan I. Epstein, Alan W. Partin et al. profile →
  19. Prognostic G leason grade grouping: data based on the modified G leason scoring system
    2013 452 citations Phillip M. Pierorazio, Patrick C. Walsh et al. British Journal of Urology profile →
  20. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy
    2018 209 citations Alan W. Partin et al. European Urology profile →

Peers

Alan W. Partin
Comparison fields: 5 of 184
  • Pulmonary and Respiratory Medicine 31.0k
  • Rheumatology 7.9k
  • Molecular Biology 7.6k
  • Surgery 6.5k
  • Cancer Research 5.4k
Replace Peter T. Scardino with:
Peter T. Scardino United States
Peter R. Carroll United States
Patrick C. Walsh United States
Theodorus van der Kwast Netherlands
Thomas M. Wheeler United States
Eric A. Klein United States
William J. Catàlona United States
David G. Bostwick United States
Jonathan I. Epstein United States
Markus Graefen Germany
Peter T. Scardino United States View profile →
Citations per field, relative to Alan W. Partin
Alan W. Partin · 1×
Citations per year, relative to Alan W. Partin
Alan W. Partin · 1×

Countries citing papers authored by Alan W. Partin

Since Specialization
Citations

This map shows the geographic impact of Alan W. Partin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan W. Partin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan W. Partin more than expected).

Fields of papers citing papers by Alan W. Partin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan W. Partin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan W. Partin. The network helps show where Alan W. Partin may publish in the future.

Co-authorship network of co-authors of Alan W. Partin

This figure shows the co-authorship network connecting the top 25 collaborators of Alan W. Partin. A scholar is included among the top collaborators of Alan W. Partin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan W. Partin. Alan W. Partin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
2023 ·Cancers ·Naseruddin Höti, T. Mamie Lih, Mingming Dong, Zhen Zhang, Leslie A. Mangold, Alan W. Partin, Lori J. Sokoll, Qing Kay Li, Hui Zhang
13
2
ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical Prostatectomy With Positive Surgical Margins
2023 ·Modern Pathology ·Daniela C. Salles, Adrianna A. Mendes, Misop Han, Alan W. Partin, Bruce J. Trock, Yuezhou Jing, Tamara L. Lotan
1
3
IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
2023 ·Urology ·(unknown), Mark Stovsky, Alan W. Partin, Yair Lotan, Jack Baniel, Martin Dineen, Jason Hafron, (unknown), (unknown), (unknown), (unknown), Eric A. Klein
2
4
Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial
2021 ·The Journal of Urology ·Hiten D. Patel, Zeyad Schwen, Jeffrey Campbell, Michael A. Gorin, Alan W. Partin, Arthur L. Burnett, Mohamad E. Allaf
3
5
Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial
2020 ·European Urology ·Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, Gregory Joice, Zeyad Schwen, Phillip M. Pierorazio, Michael H. Johnson, Trinity J. Bivalacqua, Misop Han, Michael A. Gorin, (unknown), Alan W. Partin, Christian P. Pavlovich, Mohamad E. Allaf
17
6
Complications after open and robot‐assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial
2020 ·British Journal of Urology ·Mitchell M. Huang, Zhuo T. Su, Russell E.N. Becker, Christian P. Pavlovich, Alan W. Partin, Mohamad E. Allaf, Hiten D. Patel
8
7
A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization
2020 ·Prostate Cancer and Prostatic Diseases ·(unknown), (unknown), Leslie A. Mangold, (unknown), W. Nathaniel Brennen, (unknown), Kenneth J. Pienta, Alan W. Partin, William B. Isaacs, Christian P. Pavlovich, Jun Luo
2
8
Campbell-Walsh-Wein urology twelfth edition review
2020 ·Elsevier eBooks ·Alan W. Partin
3
9
African American Men With Very Low–Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?
2013 ·Journal of Clinical Oncology ·Debasish Sundi, Ashley E. Ross, Elizabeth B. Humphreys, Misop Han, Alan W. Partin, H. Ballentine Carter, Edward M. Schaeffer
176
10
PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
2011 ·Clinical Cancer Research ·Tamara L. Lotan, Bora Gürel, Siobhan Sutcliffe, David Esopi, Wennuan Liu, Jianfeng Xu, Jessica Hicks, Ben Ho Park, Elizabeth B. Humphreys, Alan W. Partin, Misop Han, George J. Netto, William B. Isaacs, Angelo M. De Marzo
262
11
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
2010 ·Clinical Cancer Research ·Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia Creel, Kelly Mundy, S. L. Davis, Ting Wang, Roula Albadine, Luciana Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Phillip G. Febbo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, Michael A. Carducci
62
12
Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program
2010 ·Journal of Clinical Oncology ·Ashley E. Ross, Stacy Loeb, Patricia Landis, Alan W. Partin, Jonathan I. Epstein, Anna Kettermann, Zhaoyong Feng, H. Ballentine Carter, Patrick C. Walsh
201
13
Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer
2009 ·Clinical Cancer Research ·Danil V. Makarov, Sumit Isharwal, Lori J. Sokoll, Patricia Landis, Cameron Marlow, Jonathan I. Epstein, Alan W. Partin, (unknown), Robert W. Veltri
44
14
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer breakdown →
2008 ·Cancer Research ·Rong Hu, Thomas A. Dunn, Shuanzeng Wei, Sumit Isharwal, Robert W. Veltri, Elizabeth B. Humphreys, Misop Han, Alan W. Partin, Robert L. Vessella, William B. Isaacs, G. Steven Bova, Jun Luo
830
15
Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality
2007 ·Journal of Clinical Oncology ·Stephen J. Freedland, Elizabeth B. Humphreys, Leslie A. Mangold, Mario A. Eisenberger, Frederick J. Dorey, Patrick C. Walsh, Alan W. Partin
150
16
Metabolic Factors Associated with Benign Prostatic Hyperplasia
2006 ·The Journal of Clinical Endocrinology & Metabolism ·J. Kellogg Parsons, H. Ballentine Carter, Alan W. Partin, B. Gwen Windham, E. Jeffrey Metter, Luigi Ferrucci, Patricia Landis, Elizabeth A. Platz
262
17
RE: An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series [3] (multiple letters)
2004 ·The Journal of Urology ·Misop Han, Alan W. Partin, Derek Y. Chan, Patrick C. Walsh, W. Reid Pitts, Bernardo Rocco, Ottavio De Cobelli, Francesco Rocco
2
18
Report on Prostate Cancer Tumor Marker Workshop 1999
2000 ·Cancer ·Alan W. Partin, Gerald P. Murphy, Michael K. Brawer
10
19
Diagnosis of localized prostate cancer: 10 years of progress
2000 ·Current Opinion in Urology ·Mark Feneley, Alan W. Partin
11
20
The prostate-localized kallikreins: Prostate specific antigen and human kallikrein 2
1999 ·Mohammad S. Saedi, Harry G. Rittenhouse, Judith A. Finlay, Stephen D. Mikolajczyk, Alan W. Partin
1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter T. Scardino Breakdown of academic impact, for papers by Peter R. Carroll Breakdown of academic impact, for papers by Patrick C. Walsh Breakdown of academic impact, for papers by Theodorus van der Kwast Breakdown of academic impact, for papers by Thomas M. Wheeler Breakdown of academic impact, for papers by Eric A. Klein Breakdown of academic impact, for papers by William J. Catàlona Breakdown of academic impact, for papers by David G. Bostwick Breakdown of academic impact, for papers by Jonathan I. Epstein Breakdown of academic impact, for papers by Markus Graefen
Rankless by CCL
2026